Trials / Unknown
UnknownNCT01214343
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
Randomized Controlled Trial Comparing Efficacy of Sorafenib Versus Sorafenib In Combination With Low Dose Cisplatin /Fluorouracil Hepatic Arterial InfUSion Chemotherapy in Patients With Advanced Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- Sponsor
- Ministry of Health, Labour and Welfare, Japan · Other Government
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of sorafenib in combination with low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.
Detailed description
Sorafenib with Low-dose FP Group Sorafenib will be administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) for 28 days. Cisplatin at the dose of 20mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330mg/m2 will be administered continuously at day1-day5, and day8-day12 via the implanted catheter system. Sorafenib Group Sorafenib will be administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) for 28 days. The treatment regimen will be continued until radiographic or symptomatic progression, the development of unacceptable toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib with Low-dose FP | Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days. |
| DRUG | Sorafenib | Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days. |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2010-10-05
- Last updated
- 2011-06-15
Locations
30 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01214343. Inclusion in this directory is not an endorsement.